Year-End Report 2025

GOTHENBURG, SE / ACCESS Newswire / January 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2025 (Oct-Dec)Net sales amounted to SEK 226.1 million (227.6), corresponding to growth of -1 percent in SEK and organic growth of …